← All Anavex Life Sciences CORP filings

Anavex Life Sciences CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AVXL
Anavex Life Sciences CORP
10-K: Anavex 10-K: EMA Rejects Alzheimer's Drug, Losses Mount
Anavex Life Sciences reports a negative trend vote from the EMA for its Alzheimer's drug blarcamesine, alongside increased net losses and decreased cash reserves for fiscal year 2025.
NASDAQ
AVXL
Anavex Life Sciences CORP
10-K: Anavex Life Sciences Corp. Reports Full Year 2024 Results, Submits MAA to EMA for Alzheimer's Treatment
Anavex Life Sciences Corp. files its annual report, highlighting clinical trial progress, regulatory submissions, and financial results for the fiscal year ended September 30, 2024.